Zydus Lifesciences reports strong Q3 & 9M FY26 growth
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Subscribe To Our Newsletter & Stay Updated